Published in Cancer Immunol Immunother on November 28, 2007
Immunotherapy for melanoma: current status and perspectives. J Immunother (2010) 1.72
Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer (2013) 1.64
HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene (2008) 1.59
Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res (2009) 1.38
Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer (2016) 1.31
Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Invest New Drugs (2010) 1.27
Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies. J Transl Med (2010) 1.17
Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies. Proc Natl Acad Sci U S A (2011) 1.17
Combining cancer immunotherapy and targeted therapy. Curr Opin Immunol (2013) 1.09
Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer. Immunol Cell Biol (2011) 1.05
Systems biology approach to identification of biomarkers for metastatic progression in cancer. BMC Bioinformatics (2008) 1.04
An epigenetic vaccine model active in the prevention and treatment of melanoma. J Transl Med (2007) 0.99
HDAC inhibitors and immunotherapy; a double edged sword? Oncotarget (2014) 0.97
The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity. Melanoma Res (2013) 0.92
Identification of E2F1 as an important transcription factor for the regulation of tapasin expression. J Biol Chem (2010) 0.90
Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status. Br J Cancer (2011) 0.90
Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation. Mol Oncol (2015) 0.88
Role of gene methylation in antitumor immune response: implication for tumor progression. Cancers (Basel) (2011) 0.87
Post-transcriptional and epigenetic regulation of antigen processing machinery (APM) components and HLA-I in cervical cancers from Uighur women. PLoS One (2012) 0.87
Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade. Viruses (2016) 0.85
Effects of the epigenetic drug MS-275 on the release and function of exosome-related immune molecules in hepatocellular carcinoma cells. Eur J Med Res (2013) 0.82
Restoration of immune response gene induction in trophoblast tumor cells associated with cellular senescence. J Reprod Immunol (2009) 0.82
Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers. Leuk Res (2010) 0.81
Oncolytic viruses as immunotherapy: progress and remaining challenges. Onco Targets Ther (2016) 0.81
Exposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and function. Cancer Immunol Res (2014) 0.79
The combination of histone deacetylase inhibitors with immune-stimulating antibodies has potent anti-cancer effects. Oncoimmunology (2012) 0.79
Clinical use and applications of histone deacetylase inhibitors in multiple myeloma. Clin Pharmacol (2016) 0.78
Epigenetic regulations in the IFNγ signalling pathway: IFNγ-mediated MHC class I upregulation on tumour cells is associated with DNA demethylation of antigen-presenting machinery genes. Oncotarget (2014) 0.78
MHC class II regulation by epigenetic agents and microRNAs. Immunol Res (2010) 0.78
Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy. Oncotarget (2016) 0.78
Association between putative functional variants in the PSMB9 gene and risk of melanoma--re-analysis of published melanoma genome-wide association studies. Pigment Cell Melanoma Res (2013) 0.76
Host directed therapies (HDTs) and immune response signatures: insights into a role for interleukin-32. Ann Transl Med (2015) 0.76
NLRC5 elicits antitumor immunity by enhancing processing and presentation of tumor antigens to CD8(+) T lymphocytes. Oncoimmunology (2016) 0.76
A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma. Cancer Med (2016) 0.76
The Impact of Chemotherapy, Radiation and Epigenetic Modifiers in Cancer Cell Expression of Immune Inhibitory and Stimulatory Molecules and Anti-Tumor Efficacy. Vaccines (Basel) (2016) 0.75
Histone Deacetylase Inhibitors Enhance CD4 T Cell Susceptibility to NK Cell Killing but Reduce NK Cell Function. PLoS Pathog (2016) 0.75
Loss of tapasin in human lung and colon cancer cells and escape from tumor-associated antigen-specific CTL recognition. Oncoimmunology (2017) 0.75
Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy. Cancers (Basel) (2015) 0.75
The epigenetic regulation of Dicer and microRNA biogenesis by Panobinostat. Epigenetics (2016) 0.75
Understanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model. Front Pharmacol (2016) 0.75
Inferring the Impact of Regulatory Mechanisms that Underpin CD8+ T Cell Control of B16 Tumor Growth In vivo Using Mechanistic Models and Simulation. Front Pharmacol (2017) 0.75
Modulation of the Intratumoral Immune Landscape by Oncolytic Herpes Simplex Virus Virotherapy. Front Oncol (2017) 0.75
Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy. Drug Des Devel Ther (2017) 0.75
Trichostatin A Sensitizes Hepatocellular Carcinoma Cells to Enhanced NK Cell-mediated Killing by Regulating Immune-related Genes. Cancer Genomics Proteomics (2017) 0.75
Translating the histone code. Science (2001) 56.77
T cell receptor antagonist peptides induce positive selection. Cell (1994) 18.66
Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer (2006) 11.22
Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell (2003) 2.61
Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2'-deoxycytidine treatment. Int J Cancer (2001) 2.07
Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J Immunol (2000) 2.07
Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs (2005) 2.03
Antigen-processing machinery breakdown and tumor growth. Immunol Today (2000) 1.82
Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res (2005) 1.82
Targeting histone deacetylase in cancer therapy. Med Res Rev (2006) 1.69
Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res (2001) 1.66
HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. Cancer Res (2006) 1.65
Peptide antigen production by the proteasome: complexity provides efficiency. Immunol Today (1996) 1.65
Histone deacetylase inhibitor Trichostatin A induces global and gene-specific DNA demethylation in human cancer cell lines. Biochem Pharmacol (2007) 1.56
HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today (1999) 1.47
Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. Blood (2000) 1.43
Epigenetic regulation of immune escape genes in cancer. Cancer Immunol Immunother (2006) 1.30
Epigenetic aberrations and cancer. Mol Cancer (2006) 1.29
Histone deacetylase 1/mSin3A disrupts gamma interferon-induced CIITA function and major histocompatibility complex class II enhanceosome formation. Mol Cell Biol (2003) 1.16
Mastoparan, a G protein agonist peptide, differentially modulates TLR4- and TLR2-mediated signaling in human endothelial cells and murine macrophages. J Immunol (2005) 1.14
Retention of empty MHC class I molecules by tapasin is essential to reconstitute antigen presentation in invertebrate cells. EMBO J (1999) 1.13
Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity. Cancer Res (2001) 1.13
Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. Oncogene (2005) 1.13
Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6. J Immunol (2001) 1.13
Histone acetylation regulates the cell type specific CIITA promoters, MHC class II expression and antigen presentation in tumor cells. Int Immunol (2005) 1.12
Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts. Eur J Immunol (1998) 1.07
Antigen requirements for efficient priming of CD8+ T cells by Leishmania major-infected dendritic cells. Infect Immun (2005) 1.05
Histone deacetylase activity represses gamma interferon-inducible HLA-DR gene expression following the establishment of a DNase I-hypersensitive chromatin conformation. Mol Cell Biol (2001) 1.01
Restoration of the expression of transporters associated with antigen processing in lung carcinoma increases tumor-specific immune responses and survival. Cancer Res (2005) 0.98
An epigenetically altered tumor cell vaccine. Cancer Immunol Immunother (2004) 0.95
Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells. J Biol Chem (2006) 0.93
Efficient direct priming of tumor-specific cytotoxic T lymphocyte in vivo by an engineered APC. Cancer Res (1998) 0.93
Coordinate downregulation of multiple MHC class I antigen processing genes in chemical-induced murine tumor cell lines of distinct origin. Tissue Antigens (2000) 0.93
Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid. J Transl Med (2006) 0.91
Coordinated downregulation of the antigen presentation machinery and HLA class I/beta2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer. Int J Cancer (2005) 0.91
Role of TAP-1 and/or TAP-2 antigen presentation defects in tumorigenicity of mouse melanoma. Cell Immunol (2004) 0.88
Methylation-regulated expression of HLA class I antigens in melanoma. Int J Cancer (2003) 0.88
HPV16E7 mediates HADC chromatin repression and downregulation of MHC class I genes in HPV16 tumorigenic cells through interaction with an MHC class I promoter. Biochem Biophys Res Commun (2006) 0.87
Histone deacetylase inhibitors up-regulate the expression of cell surface MHC class-I molecules in B16/BL6 cells. J Antibiot (Tokyo) (1998) 0.86
Regulation of high molecular weight-melanoma associated antigen (HMW-MAA) gene expression by promoter DNA methylation in human melanoma cells. Oncogene (2006) 0.86
Chromatin repression by COUP-TFII and HDAC dominates activation by NF-kappaB in regulating major histocompatibility complex class I transcription in adenovirus tumorigenic cells. Virology (2003) 0.83
Mutation in the beta 2m gene is not a frequent event in head and neck squamous cell carcinomas. Hum Immunol (1999) 0.83
Microsatellite instability analysis in tumors with different mechanisms for total loss of HLA expression. Cancer Immunol Immunother (2000) 0.82
MicroRNA targets in immune genes and the Dicer/Argonaute and ARE machinery components. Mol Immunol (2007) 2.24
Dicer is regulated by cellular stresses and interferons. Mol Immunol (2008) 1.69
miRNA regulation of cytokine genes. Cytokine (2009) 1.39
Histone acetylation regulates the cell type specific CIITA promoters, MHC class II expression and antigen presentation in tumor cells. Int Immunol (2005) 1.12
The heat shock protein 90-CDC37 chaperone complex is required for signaling by types I and II interferons. J Biol Chem (2005) 1.05
An epigenetic vaccine model active in the prevention and treatment of melanoma. J Transl Med (2007) 0.99
Histone deacetylase regulation of immune gene expression in tumor cells. Immunol Res (2008) 0.97
An epigenetically altered tumor cell vaccine. Cancer Immunol Immunother (2004) 0.95
Exosomes from plasmacytoma cells as a tumor vaccine. J Immunother (2004) 0.94
DNA alkylating agents alleviate silencing of class II transactivator gene expression in L1210 lymphoma cells. J Immunol (2002) 0.92
Apoptotic and necrotic cells induced by different agents vary in their expression of MHC and costimulatory genes. Mol Immunol (2004) 0.84
Dicer in immune cell development and function. Immunol Invest (2013) 0.83
Restoration of immune response gene induction in trophoblast tumor cells associated with cellular senescence. J Reprod Immunol (2009) 0.82
Mild hyperthermia enhances the expression and induces oscillations in the Dicer protein. Int J Hyperthermia (2013) 0.80
Spatial distribution of histone methylation during MHC class II expression. Mol Immunol (2007) 0.80
Serum amyloid P component induces neuronal apoptosis and beta-amyloid immunoreactivity. Brain Res (2003) 0.79
MHC class II regulation by epigenetic agents and microRNAs. Immunol Res (2010) 0.78
The major histocompatibility complex class II transactivator is differentially regulated by interferon-gamma and transforming growth factor-beta in microglial cells. J Neuroimmunol (2005) 0.76
Granulocyte-macrophage colony-stimulating factor (GM-CSF) restores allostimulatory function to accessory cells in patients with AIDS. HIV Clin Trials (2002) 0.75